Ads
related to: pfizer
Search results
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 20 hours agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said ...
Thinking Of Buying Pfizer For Its 5.8% Dividend Yield? Consider This Alternative Option Instead
Benzinga via Yahoo Finance· 7 days agoPfizer Inc. (NYSE:PFE) has long been a favorite among income investors, thanks to its generous...
KP.3 is the dominant COVID-19 variant in the US: Latest on test positivity, deaths, symptoms
USA Today· 14 hours agoCases of the latest COVID-19 variant, also known as KP.3, are on the rise in the United States....
Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne muscular...
FierceBiotech· 1 day agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 18 hours agoPharma giant Pfizer Inc. (NYSE: PFE) announced on Wednesday after markets closed that its gene...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 12 hours agoWho should wait, and who should get vaccinated now? The CDC advises that everyone ages 5 and older...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 1 day agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Weik Capital Management Sells 10,839 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 5 days agoWeik Capital Management decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 26.3% in the 4th quarter, according to the company in its most recent filing with ...
Pfizer Inc. (NYSE:PFE) Shares Sold by Cresset Asset Management LLC
ETF DAILY NEWS· 2 days agoCresset Asset Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 13.5% in the fourth quarter, according to the company in its most recent disclosure ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 2 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...